NeurologyLive

06/23/2025

Is once-nightly sodium oxybate changing the treatment conversation? 🤔

At , Richard Bogan, MD, FCCP, FAASM, associate clinical professor at the University of South Carolina School of Medicine, broke down key findings from several presentations exploring its potential ⚡

Read Bogan’s full perspective in our Q&A:

Richard Bogan, MD, FCCP, FAASM, an associate clinical professor at the University of South Carolina School of Medicine, discussed a bevy of presentations from the 2025 SLEEP Annual Meeting highlighting the effects of once-nightly sodium oxybate.

06/23/2025

Anita Shelgikar, MD, a clinical professor at the University of Michigan and president of the American Academy of Sleep Medicine, provided post-conference perspectives on the meeting, giving clinicians insights on the latest in research and treatment updates 🤔

Read now:

Anita Shelgikar, MD, a clinical professor at the University of Michigan and president of the American Academy of Sleep Medicine, provided post-conference perspectives on the 2025 SLEEP meeting, giving clinicians insights on the latest in research and treatment updates.

06/22/2025

In recent news, Biogen has initiated a new phase 3 trial dubbed BRAVE that assesses the therapeutic potential of omaveloxolone (Skyclarys), the only FDA-approved therapy for adults with , in pediatric patients living with the disease.

Read More:

Biogen recently launched a pivotal phase 3 trial for omaveloxolone, aiming to explore its safety and efficacy in pediatric patients with Friedreich ataxia.

06/22/2025

At the 2025 , Marcela Romero-Reyes, DDS, PhD, FAHS, of University of Maryland, Baltimore, discussed a promising and potentially safer therapeutic approach for managing trigeminal neuropathic pain. American Headache Society®

06/22/2025

📰 🧠 From new treatment data to evolving care strategies for patients, the 2025 delivered the latest updates in & research. American Headache Society® 🤕💊

🔎 Explore our news coverage and hear from experts in the field that attended this year's annual meeting in Minneapolis, Minnesota: https://hubs.li/Q03t4GQ70

06/21/2025

In collaboration with The ALS Association, experts discussed promising developments in treatment, including gene-targeted therapies, emerging biomarkers, and AI-powered tools for diagnosis and patient support 🎙️🧠

Watch now: https://hubs.li/Q03sXdMg0
(WATCH TIME: 5 minutes)

06/21/2025

👏🎬 Another great round of interviews with experts in & here at the 2025 in Minneapolis, Minnesota! Thank you to everyone who came out today to speak with us! American Headache Society®

Featured:
- Rami Burstein, PhD
- Kristen Pocock, MD
- Chia-Chun Chiang, MD

View our coverage here: https://hubs.li/Q03t4H4z0

06/21/2025

Aetna has joined Anthem and UnitedHealthcare care in providing coverage for the PoNS device, a neuromodulation therapy using tongue stimulation to address gait issues in . Helius Medical continues efforts to expand access and align rates with VA/DoD standards 📈

Learn more:

Helius Medical Technologies expands access to its PoNS device for patients with MS as Aetna joins major payers in coverage, enhancing treatment options.

06/21/2025

The director of outpatient care at Jefferson Health Headache Center weighed in on the future of PACAP as a target and previewed upcoming innovations at the 2025 🗣️

Watch now: https://hubs.li/Q03sTwdZ0
( 📽️WATCH TIME: 3 minutes)

The director of outpatient care at Jefferson Headache Center weighed in on the future of PACAP as a migraine target and previewed upcoming innovations at the 2025 AHS Annual Meeting. [WATCH TIME: 3 minutes]

06/21/2025

Good morning from Minneapolis, Minnesota! It is Day 3 of the 2025 and we are all set up for interviews. Our first interview of the day was with Jennifer Robblee, MD, MSc, of Barrow Neurological Institute, who spoke about a consensus definition on refractory ! American Headache Society®

06/21/2025

The director of the John A. Schafer, MD Achievement Center at Dignity Health discussed the effect of loneliness and social isolation on individuals living with multiple sclerosis 🎙️

Read now:

The director of the John A. Schafer, MD Multiple Sclerosis Achievement Center at Dignity Health discussed the effect of loneliness and social isolation on individuals living with multiple sclerosis.

06/21/2025

China’s NMPA recently approved telitacicept (Remegen)—Marketed as the first drug to target both BLyS and APRIL, telitacicept may offer a revolutionary treatment option for patients with myasthenia gravis ( ) 💊

Read more now:

Marketed as the first drug to target both BLyS and APRIL, Telitacicept may offer a revolutionary treatment option for patients with myasthenia gravis.